Delivery Order SPE2DB20D7059-SPE2DB25FGRC6
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the pharmaceutical product Emgality 120 mg/mL pen on May 20, 2025, with a ceiling value of $1,037.40. This firm fixed-price contract is non-competitive and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle valued through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Emgality 120 mg/mL pen injectors, valued at $1,556.10. This is a firm fixed-price delivery order with an ultimate completion date of August 29, 2025, and represents a non-competitive set-aside award. The pharmaceutical will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary distribution operations. This...
- The Defense Logistics Agency awarded a delivery order valued at $3,309.37 to AmerisourceBergen Drug Corp for the supply of Emgality 120 mg/ml pen injectors. This firm fixed price, competitively awarded contract was issued on August 5, 2025, with an ultimate completion date of August 6, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $2,457.00 to AmerisourceBergen Drug Corp for the supply of Emgality 120 mg/ml pen injectors. This competitive, firm fixed-price delivery order was executed on August 25, 2025, with an ultimate completion date of August 26, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The contract represents a child order under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Emgality 120 mg/mL pen injectors, with a ceiling value of $6,822.36. This firm fixed-price delivery order, awarded on August 19, 2025, represents a child contract under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The award was made through open competition with no set-aside designation. AmerisourceBergen will perform this supply delivery from its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pens on September 11, 2025, with a ceiling value of $1,037.40 under a firm fixed price contract type. This order represents a non-competitive set-aside delivery against AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate...
- The Defense Logistics Agency awarded a delivery order valued at $1,037.40 to AmerisourceBergen Drug Corp for the supply of Emgality 120 mg/ml pens on June 13, 2025. This contract, issued on a firm fixed-price basis with an ultimate completion date of June 16, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance and is a major pharmaceutical distributor providing critical medical supplies to...
- The Defense Logistics Agency awarded a delivery order valued at $1,401.40 to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen (injectable migraine treatment) with a completion date of September 17, 2025. This competitively awarded, firm fixed-price delivery order represents a single transaction within AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The contract specifies performance at the company's Conshohocken, Pennsylvania facility, where...
- The Defense Logistics Agency (DLA) awarded a $3,457 delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors on September 18, 2025, with an ultimate completion date of September 19, 2025. This competitive, firm fixed-price contract was issued without set-aside designation and represents a child order under AmerisourceBergen's larger contract vehicle with DLA. The product—Emgality (erenumab)—is a monoclonal antibody used for migraine prevention, reflecting the...
- The Defense Logistics Agency awarded a delivery order valued at $2,334.15 to AmerisourceBergen Drug Corp for the supply of Emgality 120 mg/ml pen injectors. The award, issued on September 3, 2025, with an ultimate completion date of September 4, 2025, represents a firm fixed price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, fulfilled this requirement as a competitive award under its existing contract vehicle with the...
- SPE2DB20D7059Indefinite Delivery Contract
- SPE2DB20D7059-SPE2DB25FGRC6Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Emgality 120 mg/ml pen prefilled syringes, with a ceiling value of $1,424.74. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 8, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime vendor agreement running through December 2026 that enables the company to supply a comprehensive range of pharmaceutical products and medical commodities to support military healthcare operations globally. AmerisourceBergen Drug Corp is a major pharmaceutical distributor headquartered in Pennsylvania that serves as a critical federal medical procurement vendor, particularly for military and veteran healthcare systems. The company's extensive portfolio of federal contract awards demonstrates its capability to meet DLA requirements through open competition, delivering brand-name and generic medications, vaccines, medical devices, and specialized healthcare supplies across multiple therapeutic domains. This delivery order for Emgality, a migraine treatment medication, exemplifies the company's role in fulfilling specialized pharmaceutical needs within the federal medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 9/5/25 |